ARB Class Buck Medicine - Clinical Application of Kandisatan

Lowering blood pressureis the key to the benefits of applying a variety of antihypertensive drugs
based on the evidence from existing clinical trials, the European Society forHypertension(ESH) and the European Society ofCardio
logy (ESC) in their 2007 new guidelines forhypertension, continue to emphasize that lowering blood pressure is key to the benefits of applying a variety of antihypertensive drugsFive broad types of antihypertensive drugs, such as diuretics, beta blockers, calcium ion antagonists, angiotensin conversion enzyme inhibitors (ACEI) and angiotensin receptor antagonists (ARB), can be used as the primary treatment for patients withhigh blood pressureAt the same time, the guidelines clearly list specific indications for various types of drugsAmong them, the aRB drug's adaptation mainly includes heart failure, myocardial infarction, diabetic nephropathy, proteinuria, trace albuminuria, left ventricular hypertrophy, atrial fibrillation, metabolic syndrome and ACEI-induced cough
hypertensionpatientsOn the basis of adhering to the principle of clinical trial evidence, we should choose the drug with strong antihypertensive efficacy
ARB is a blood-active antihypertensive drug, which mainly achieves the antihypertensive effect by blocking the type 1 agiotensin receptor (AT1) In recent years, ARB has been the fastest-growing class of antihypertensive drugs in many countries However, there are very different effects on antihypertensive effects and clinical trial evidence Clinicians should choose those who have strong antihypertensive effect on the basis of adhering to the principle of clinical trial evidence when choosing drugs In this way, the risk of cardiovascular disease can be minimized at a low economic cost Among the current aRB drugs commonly used, Kandysatin has a very obvious advantage in the efficacy of buck Studies have shown that Kandysatin has the strongest inhibitory effect on AT1 receptors In addition, Kandysatan has the strongest inhibitory effect on vasotensin-induced vasoconstriction In the process of cleaning the blood vessels that had inhibited them, the inhibitory effect of Kandisatan on the contraction of blood vessels also did not decrease This difference in action between different ARbBs is independent of drug concentration and exposure time and is most likely determined by the characteristics of the drug itself Kandisatan not only has a strong effect on receptor antagonying, but also lasts up to 24 hours Some researchers believe that the good receptor antagonism of Kandisatan is likely to be related to its slow separation from the receptor, slow removal from tissue, and structural regulation of the receptor A meta-analysis of a clinical trial involving four ARbs of buck therapy showed that in FDA-registered trials in the United States, the blood pressure-reducing pallients of chloratan, zimsatin, Ibesatan and Kandisatan were 5.6 (3.6 to 7.5) mmHg, respectively, in the case of a standard dose of a drug 5.8 (5.0 to 6.6) mmHg, 6.9 (5.9 to 7.9) mmHg and 7.5 (6.1 to 8.9) mmHg, of which the difference between Kandysatan and shatan is significant (P-0.01) Kandisatan not only has a strong pressure-lowering effect, but also lasts up to 24 hours In a controlled study of Kandysatan and chloratan, the blood pressure difference in the 100 mg group of clossatin and the 16 mg group of Kandisatan was 4.2/2.2 mmHg, respectively, 36 hours after the last dose Several clinical trials provide kandisatan applications based on Kandisatan has conducted large sample clinical trials in a variety of patients with cardiovascular disease The CHARM trial was a large sample clinical trial study of large-sample saucan-controlled studies in patients with symptomatic heart failure to see if kandysatin could reduce cardiovascular death and heart failure hospitalization A total of 7601 patients from 26 countries participated in the trial Like the left ventricular blood score and whether acei-i drugs were being used prior to selection were divided into three subgroups: patients with a blood score below 40%, those who did not use ACEI because they were intolerable, who were given candysatin or a corresponding placebo (alternative); The results showed that at 6 months of follow-up, the reduced systolic and diastolic pressure advantage in the Kandisatan group compared to placebo was 5.2/3.0 mmHg At the end of the follow-up, Kandysatin significantly reduced the risk of cardiovascular death (-12%) and the risk of hospitalization for heart failure (-21%) compared to the placebo group, while significantly reducing the overall mortality rate (-9%) The benefits of reduced death and heart failure hospitalization were very consistent in three subgroups, indicating that Kandisatan significantly improved the prognosis of patients with heart failure, regardless of whether the left ventricle blood score was normal and whether the patient used ACEI The Case-J study was a large sample of 4,728 patients in Japan with high-risk hypertension, and was designed to evaluate the effects of kandysatin on cardiovascular events compared to the calcium ion antagonic antagonic acid All subjects were high-risk hypertension patients, such as blood pressure of more than 180/110 mmHg, combined type 2 diabetes, stroke history, proteinuria and peripheral vascular disease The initial dose of 4 mg in the Kandisatan group can be gradually increased to 8 mg and 12 mg, and the initial dose of the ammonia chlorpyrifos group is 2.5 mg, which can be gradually increased to 5 mg and 10 mg The results showed that during the three-year follow-up period, the two groups of Kandisatan and ammonia chlorite had similar antihypertensive effects, and there was no significant difference in effect on the compound cardiovascular endpoint In addition, the Canditysatan Clinical TrialS study included a placebo-controlled SCOPE study of cardiovascular complications and dementia in elderly patients in northern Europe, a placebo-controlled TROPHY study in prehypertension patients, and a casebo-controlled disease prevention of hypertension in patients with acute stroke The ONS 11 study, among others, included a placebo-controlled dI-RECT study of retinopathy level i-level and secondary prophylactic prophylaxis in patients with diabetes and a CATCH study on the prevention of left ventricular hypertrophy compared to ACEI in inapris in patients with hypertension These studies have been or will further enrich clinical trial evidence of Kandysatan's buck and the prevention of cardiovascular complications (Wang Jiguang; Huang Weifang)